Charles Schwab Investment Management Inc Puma Biotechnology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 127,443 shares of PBYI stock, worth $657,605. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,443
Previous 118,254
7.77%
Holding current value
$657,605
Previous $350,000
24.86%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding PBYI
# of Institutions
125Shares Held
33.7MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$21.3 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$19.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$18.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$10.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$9.67 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $235M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...